Pancreatic Center Clinical Trials
Clinical trials are studies that are important for discovering new ways to diagnose and treat disease. They often involve collaboration across multiple departments, with researchers involved in design, testing and analysis of these studies. The ultimate goal of clinical trials is to improve the lives of our patients as we strive to improve our standards of care and patient outcomes through medications, therapies, genetics, diet and better screening.
Trials also offer our patients an avenue for gaining early access to promising treatments.
-
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors. +
Phase I Open-Label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination with an Anti-PD-1 mAb in Patients with Advanced or Metastatic Solid Tumors.
Protocol No: 1456-0001
Age Group: Adult
Disease Sites: Eye and Orbit, Lip, Oral Cavity and Pharynx, Pancreas
NCT Id: NCT05155332
Phase: I
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14732
File Name: UPDATED Subject Eligibility _Screening Checklist_1456-001_Part One (2).docx
URL:
Objective
To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for BI 1831169 both as monotherapy and in combination with an anti-PD-1 antibody and to assess the efficacy, safety and tolerability when given via intravenous and intratumoral routes.
-
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3) +
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
Protocol No: 300383
Age Group: Adult
Disease Sites: Soft Tissue
NCT Id: NCT07218926
Phase: III
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To compare the efficacy of IDRX-42 to that of sunitinib in participants with metastatic and/or unresectable GIST after failure of imatinib therapy, as evidenced by PFS
-
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy +
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
Protocol No: 75276617AML3001
Age Group: Adult
Disease Sites: Myeloid and Monocytic Leukemia
NCT Id: NCT06852222
Phase: III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 16972
File Name: Subject Eligibility _Screening Checklist_JNJ75276617AML3001.docx
URL:
Objective
The primary objective is to determine whether the addition of bleximenib to VEN+AZA significantly improves the dual primary endpoints of CR rate or OS compared with VEN+AZA in participants with ND KMT2Ar or NPM1mAML who are ineligible for intensive chemotherapy
-
Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs SOC in Patients with Recurrent Glioblastoma. +
Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs SOC in Patients with Recurrent Glioblastoma.
Protocol No: A072201
Age Group: Adult
Disease Sites: Brain and Nervous System, Eye and Orbit
NCT Id: NCT06325683
Phase: II
Principal Investigators: Alfredo Voloschin, MD
Objective
To compare the restricted mean survival time for overall survival between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care chloroethylcyclohexylnitrosourea (CCNU) (lomustine).
-
A PHASE 3, MULTICENTER, CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB ERBUMINE IN PARTICIPANTS WITH ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA +
A PHASE 3, MULTICENTER, CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB ERBUMINE IN PARTICIPANTS WITH ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA
Protocol No: AB-218-G203
Age Group: Adult
Disease Sites: Brain and Nervous System
NCT Id: NCT05303519
Phase: II
Principal Investigators: Alfredo Voloschin, MD
Objective
This is a Phase 2, multicenter, clinical study to evaluate the efficacy, safety, and PK of safusidenib in participants with IDH1-mutant glioma.
-
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3) +
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)
Protocol No: ALLO-501A-202
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06500273
Phase: II
Principal Investigators: Juan Varela MD, PhD
Objective
This study is testing a new type of cell therapy to see if it can help prevent lymphoma from coming back in people who still have small amounts of cancer after their first treatment.
-
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma +
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Protocol No: BGB-A317-316
Age Group: Adult
Disease Sites: Esophagus, Stomach
NCT Id: NCT07043400
Phase: III
Principal Investigators: Raji Shameem, MD
Objective
This study is testing two different ways of giving a medicine called tislelizumab to patients with advanced stomach or gastroesophageal junction (GEJ) cancer. One way is by injection under the skin (called SC injection) and the other is through a vein (IV infusion). Both methods are given along with chemotherapy.
-
A Randomized, Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) +
A Randomized, Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Protocol No: D702AC00001
Age Group: Adult
Disease Sites: Gastric Disease
NCT Id: NCT06764875
Phase: III
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To find out if adding the medicine rilvegostomig to trastuzumab deruxtecan and chemotherapy works better and is as safe as the current standard treatment of pembrolizumab with trastuzumab and chemotherapy for people with HER2 positive stomach or GE junction cancer that has spread or cannot be removed.
-
Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma +
Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Protocol No: GNS561-222-1
Age Group: Adult
Disease Sites: Bile Duct Cancer (Cholangiocarcinoma)
NCT Id: NCT05874414
Phase: I/II
Principal Investigators: Omar Kayaleh, MD
Objective
This study will evaluate the safety of the drug combination GNS561 and trametinib and determine whether any significant treatment-related side effects occur during the first treatment cycle. It will also assess how well the drugs work by measuring how many patients have their tumors shrink or disappear.
-
A Phase 2, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma +
A Phase 2, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Protocol No: GO45434
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06806033
Phase: II
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 14973
File Name: Subject Eligibility _Screening Checklist_GO45434.docx
URL:
Objective
This study will evaluate the optimization of the CRS profile for the Glofit-GemOx treatment regimen in patients with R/R DLBCL, using optimized regimen of steroids and a revised infusion and monitoring regimen to optimize the CRS profile of this treatment combination.
-
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) +
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-Positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Protocol No: IMCGP100-203
Age Group: Adult
Disease Sites: Melanoma, Skin
NCT Id: NCT05549297
Phase: II/III
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 14448
File Name: Subject Eligibility _Screening Checklist Version 19JUL2024 (1).docx
URL:
Objective
To study if the drug tebentafusp, alone or with another therapy, can help people with advanced melanoma live longer and reduce cancer activity in their blood.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357) +
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)
Protocol No: INCA34176-357
Age Group: Both
Disease Sites: Other Hematopoietic
NCT Id: NCT06585774
Phase: III
Principal Investigators: Juan Varela MD, PhD
Objective
To compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe cGVHD.
-
A Phase 2, Multicenter, Open-Label Study of Lifileucel (Tumor-Infiltrating Lymphocytes [TIL]) in Participants with Previously Treated Advanced Endometrial Cancer +
A Phase 2, Multicenter, Open-Label Study of Lifileucel (Tumor-Infiltrating Lymphocytes [TIL]) in Participants with Previously Treated Advanced Endometrial Cancer
Protocol No: IOV-END-201
Age Group: Adult
Disease Sites: Other Female Genital
NCT Id: NCT06481592
Phase: II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 20182
File Name: Subject Eligibility _BASELINE Checklist_IOV-END-201 part 2 .docx
URL:
Objective
To evaluate the efficacy of lifileucel as measured by objective response rate per Response Evaluation Criteria in Solid Tumors in participants with dMMR or pMMR tumors based on the central laboratory assessment of MMR status
-
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer +
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Protocol No: IOV-GM1-201
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05361174
Phase: II/III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 11553
File Name: Subject Eligibility _Baseline Checklist GM1.docx
URL:
Objective
This study is testing a new type of immune cell therapy called IOV-4001. It's being used in people with advanced melanoma or lung cancer to see if it is safe and whether it can help shrink tumors.
-
A Phase 3, Multicenter, Randomized, Open-Label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma +
A Phase 3, Multicenter, Randomized, Open-Label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma
Protocol No: IOV-MEL-301
Age Group: Adult
Disease Sites: Melanoma, Skin
NCT Id: NCT05727904
Phase: III
Principal Investigators: Juan Varela MD, PhD
Eligibility Document -
Attachment Id: 21212
File Name: Subject Eligibility _Screening Checklist IOV-MEL-301.docx
URL:
Objective
This study is looking at whether combining lifileucel with pembrolizumab helps patients more than pembrolizumab alone by measuring how many people respond to treatment and how long their cancer stays stable over five years.
-
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2) +
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE;FL-2)
Protocol No: M22-003
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06191744
Phase: III
Principal Investigators: Jose Sarriera, MD
Eligibility Document -
Attachment Id: 6409
File Name: Subject Eligibility _Screening Checklist M22-003_Version 2.0 dated 09Feb2024.docx
URL:
Objective
This study is testing if a new drug combination (epcoritamab with rituximab and lenalidomide) works better than standard chemotherapy for adults with previously untreated follicular lymphoma.
-
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 with or Without Bevacizumab as First-line Treatment of Participants with KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) +
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 with or Without Bevacizumab as First-line Treatment of Participants with KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Protocol No: MK-1084-012
Disease Sites: Anus, Colon, Other Digestive Organ, Rectum
NCT Id: NCT06997497
Phase: III
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
To evaluate the safety and tolerability of treatment with MK-1084, cetuximab, and mFOLFOX6
-
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) +
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
Protocol No: MK-2140-010
Age Group: Adult
Disease Sites: Non-Hodgkin's Lymphoma
NCT Id: NCT06717347
Phase: III
Principal Investigators: Daniel Anscher,MD
Objective
To find out if adding the new medicine zilovertamab vedotin to standard chemotherapy (R-CHP) works better and is as safe as the current standard (R-CHOP) as the first treatment for diffuse large B-Cell lymphoma.
-
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis +
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Protocol No: ML44719
Age Group: Adult
Disease Sites: Liver
NCT Id: NCT06096779
Phase: II
Principal Investigators: Jacobo Hincapie-Echeverri, MD
Objective
This study is testing a new treatment in people with advanced liver cancer (hepatocellular carcinoma) who also have moderate liver damage. The goal is to see how safe the treatment is and to track any side effects.
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors +
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol No: MRNA-4359-P101
Age Group: Adult
Disease Sites: Lung, Melanoma, Skin
NCT Id: NCT05533697
Phase: I/II
Principal Investigators: Yuanbin Chen, MD
Eligibility Document -
Attachment Id: 20312
File Name: Subject Eligibility _Screening Checklist Version 28JUL2025 MRNA-4359-P101.docx
URL:
Objective
The main goal of this study is to find the safest dose of the study drug and see how well it works against solid tumors. We will also check for any side effects and how the cancer responds to treatment. This helps us learn if the drug can be used safely and effectively.
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease +
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Protocol No: NRG-GI008
Age Group: Adult
Disease Sites: Colon
NCT Id: NCT05174169
Phase: II/III
Principal Investigators: Omar Kayaleh, MD
Eligibility Document -
Attachment Id: 13913
File Name: NRG-GI008 CIRCULATE NA Subject Eligibility _Step 1-Study Entry Screening Checklist v4.0 08Jul2025.docx
URL:
Objective
This study is testing whether a blood test called ctDNA can help guide chemotherapy after surgery for stage II or III colon cancer. The goal is to see if using this test can safely reduce how many patients need chemotherapy or help give it only to who really need it, based on signs of cancer in the blood.
-
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors +
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors
Protocol No: OBX115-23-01
Age Group: Adult
Disease Sites: Multiple Myeloma
NCT Id: NCT06060613
Phase: I/II
Principal Investigators: Tirrell Johnson, MD
Eligibility Document -
Attachment Id: 19652
File Name: OBX Subject Eligibility _Baseline Checklist Version 19MAR2025 2.docx
URL:
Objective
This study is testing a new kind of cell therapy called OBC-115 to see if it is safe and effective in people with advanced sold tumors.
-
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck +
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Protocol No: RTOG-1216
Age Group: Adult
Disease Sites: Esophagus, Eye and Orbit, Larynx, Lip, Oral Cavity and Pharynx
NCT Id: NCT01810913
Phase: II/III
Principal Investigators: Rafael Manon, MD
Eligibility Document -
Attachment Id: 7714
File Name: RTOG 1216 Eligibility Final.docx
URL:
Objective
This study is testing which treatment works best after surgery for certain types of head and neck cancer. All patients receive radiation, but the study compares three options: radiation with cisplatin, radiation with docetaxel and cetuximab, or radiation with cisplatin and atezolizumab. The goal is to find out which option helps people live longer and keeps the cancer from coming back.
Navigate Your Health
Find a Cancer Physician
Find a Cancer Physician
Meet our doctors who specialize in the full range of cancer care. Our team of experts has experience in a variety of specialty areas. Together, we provide comprehensive evaluation, diagnosis and treatment options.
Learn More
Patient Portal
Patient Portal
If you are a patient at Orlando Health Cancer Institute, our free online patient portal provides an easy and secure way to manage your health information. Reach us from any location at a time that’s convenient for you.
Learn More
Virtual Visit
Virtual Visit
Need to talk with a doctor, but don’t want to leave your home? Try our virtual visit (telehealth) option to connect with a physician from your phone, tablet or computer.
Learn More
ER Wait Times
Thursday, February 19, 2026 4:12 AM
|
|
Wait Time | |
|---|---|---|
| Orlando Health - Health Central Hospital | Directions | 0 min |
| Orlando Health Arnold Palmer Hospital for Children | Directions | 305 min |
| Orlando Health Bayfront Hospital Emergency Room | Directions | 35 min |
| Orlando Health Dr. P. Phillips Hospital | Directions | 5 min |
| Orlando Health Emergency Room - Blue Cedar | Directions | 0 min |
| Orlando Health Emergency Room - Crossroads | Directions | 0 min |
| Orlando Health Emergency Room - Four Corners | Directions | 4 min |
| Orlando Health Emergency Room - Lake Mary | Directions | 6 min |
| Orlando Health Emergency Room - Longwood | Directions | 0 min |
| Orlando Health Emergency Room - Osceola | Directions | 10 min |
| Orlando Health Emergency Room - Pinellas Park | Directions | 3 min |
| Orlando Health Emergency Room - Randal Park | Directions | 0 min |
| Orlando Health Emergency Room - Reunion Village | Directions | 6 min |
| Orlando Health Emergency Room - Waterford Lakes | Directions | 0 min |
| Orlando Health Horizon West Hospital | Directions | 0 min |
| Orlando Health Melbourne Hospital | Directions | 2 min |
| Orlando Health Orlando Regional Medical Center | Directions | 138 min |
| Orlando Health Sebastian River Hospital | Directions | 2 min |
| Orlando Health South Lake Hospital | Directions | 3 min |
| Orlando Health St. Cloud Hospital | Directions | 11 min |